Patent Application
20240374569
The instant application contains a Sequence Listing which is submitted herewith in electronically readable XML format via EFS-Web, and is hereby incorporated by reference in its entirety. The electronic Sequence Listing file is filed electronically on Sep. 22, 2022 and is named “25824-517243_Sequence-listing.XML” and is 100,052 bytes in size.
The present disclosure relates to the use of selective HDAC3 inhibitors for the treatment Langerhans cell sarcoma and Langerhans cell histiocytosis.
Dendritic cells (DC) are a heterogeneous group of professional antigen presenting cells (APC) bridging innate and adaptive immunity. Being the sole DC subtype residing at the epidermis, Langerhans cells (LC) constitute 1-2% of epidermal cells and characteristically express C-type lectin langerin, which composes Birbeck granules, the hallmark organelle of LCs. Located in the skin, the body's first line of defense, immature epidermal LCs constantly capture external and internal antigens and migrate to nearby draining lymph nodes (LNs), where they complete maturation process and present antigens to naïve T cells. These mature LCs also secrete cytokines and provide costimulatory signals to influence the decision of T cell responses between immunity and tolerance. As potent immunoregulatory cells, LCs participate in the pathogenesis of various skin disorders, including infection, allergy, autoimmunity and cancer.
Unlike conventional DCs (cDC), epidermal LCs display a unique pattern of ontogeny as well as maintenance. cDCs originate from hematopoietic stem cells within the bone marrow (BM) and are rapidly regenerated by their BM precursors in the adult. By contrast, LCs are derived from embryonic yolk sac erythro-myeloid progenitors and can self-maintain by local proliferation independent of adult hematopoiesis during steady state. However, when local inflammation causes a loss of LCs, the LC compartment is reconstituted by “short-term” LCs, which develop from peripheral blood Gr-1hi monocytes and “long-term” LCs derived from BM. Notably, the ensemble of transcription factors that govern LC homeostasis is different from that for cDCs, although detailed mechanism still remains elusive.
Histone acetylation is an essential post-translational modification of genetic programming, and it is reciprocally regulated by histone acetyltransferases and histone deacetylases (HDACs). HDACs have long been viewed as transcriptional corepressors that regulate chromatin remodeling and gene transcription. Nonetheless, recent studies have shown that HDACs also function as coactivators that deacelylate histone proteins in chromatin to activate gene transcription. Accordingly, the inhibition of HDACs can lead to prominent anti-cancer effects. Accumulating evidence shows that HDAC inhibitors (HDACi) not only dysregulates cDC-mediated T helper cell activation but also suppresses in vitro cDC differentiation from the BM and from the monocyte stages. However, the specific role of individual HDACs in the development, homeostasis and function of epidermal LCs remains unexplored.
The classical HDAC family has 11 members and is classified into three groups: class I RPD3-like proteins (HDAC 1, 2, 3, and 8), class II HDA1-like proteins (HDAC 4, 5, 6, 7, 9, and 10), and a solitary class IV HDAC (HDAC11). HDAC3 is a member of the class I HDACs, and its four different splicing variants have been identified as HD3α, -β, -γ, and -δ. HDAC3 is distinctive within the HDAC family because it is expressed not only in the nucleus but also in the cytoplasm and on the plasma membrane. HDAC3 is also a component of the nuclear receptor co-repressor complex and so has distinct molecular and physiological functions.
HDAC3 is a class I member of HDAC superfamily and plays a critical role in many biological processes, including circadian rhythm of hepatic lipogenesis, intestinal homeostasis maintenance, hematopoietic stem/progenitor DNA replication, brown adipocyte tissue thermogenesis and oocyte maturation. HDAC3 also controls the differentiation of several cell lineages, including regulatory T cells, endothelial cell and osteoblasts.
In addition, HDACs play an important role in cell proliferation and differentiation. HDAC inhibition has been demonstrated modulating the balance between pro- and anti-apoptotic proteins, upregulating the intrinsic and extrinsic apoptosis pathway, and leading to cell cycle arrest. Thus, HDACs are a compelling therapeutic target for cancer therapy. Some HDAC inhibitors have been shown to induce differentiation and cell death in myeloid and lymphoid model systems (Melnick et al., Current Opinion in Hematology 2002, 9, 322).
Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder and standard-of-care treatment remains suboptimal. Histiocytic disorders are a family of diseases most commonly due to persistent mitogen-activated protein kinase (MAPK) signaling in mononuclear phagocytes (MNPs) and their precursors. Within this family, LCH is the most common and predominantly affects children with a similar incidence to childhood Hodgkin lymphoma or acute myeloid leukemia (2.6 to 8.9 cases per million individuals per year). The presence of oncogenic drivers, resistance to apoptosis, self-sufficiency in growth signals, and the ability to invade tissues designated LCH as a type of cancer, although recent data and an evolving perspective on the disease suggests ‘inflammatory myeloid neoplasm’ is a more accurate term. LCH lesions can develop within virtually any organ, leading to a wide range of severity and comorbidities. Current standard of care employs a combination of chemotherapeutic and steroidal anti-inflammatory drugs, which exhibit significant toxic side-effects1. MEK-inhibitors (MEKi), which block MAPK signaling, have shown promise in clinical trials, but they too exhibit toxicity and cessation of MEKi leads to a high rate of LCH recurrence (only ˜50% of patients have progression-free survival). Patients who do not respond to treatment may have lifelong complications such as neurodegenerative LCH (LCH-ND), and rescue therapy remains suboptimal.
Langerhans cell sarcoma (LCS) is a neoplastic proliferation of Langerhans cells with notably malignant cytological features, and Langerhans cell histiocytosis (LCH) is a disease characterized by clonal expansion of myeloid precursors that differentiate into CD1a/CD207 in lesions. In a first aspect, the present disclosure provides methods for the prevention, therapeutic treatment, and amelioration of symptoms associated with Langerhans cell histiocytosis (LCH) and Langerhans cell sarcoma (LCS) by administering one or more s HDAC3 inhibitors to a subject in need thereof. In various embodiments, the HDAC3 inhibitor is a selective HDAC3 inhibitor.
In various embodiments, the present disclosure provides methods for the treatment of LCH and LCS in the absence of any other active agents. In some preferred embodiments, LCH and LCS is treated with the selective HDAC3 inhibitors described herein and one or more adjunct or secondary active agents, for example, a chemotherapy agent, an immunotherapy agent, or a MAPK inhibitor, for example, dabrafenib, trametinib, tovorafenib, vemurafenib, GSK2118436 (GSK436) or combinations thereof, wherein the HDAC3 inhibitor and the one or more secondary active agents are administered to the subject in need thereof, concomitantly or separately.
In a third aspect the present disclosure provides a use of a HDAC3 inhibitor for the manufacture of a medicament for preventing or treating LCH or LCS in a subject, comprising administering an effective or therapeutically effective dose to the subject that results in the prevention or treatment of LCH or LCS.
In a fourth aspect, the present disclosure provides a use of a HDAC3 inhibitor for the prevention or treatment of LCH or LCS, comprising administering an effective or therapeutically effective dose to the subject that results in the prevention or treatment of LCH or LCS.
The foregoing and other objects, features, and advantages will be apparent from the following description of particular embodiments of the present disclosure, as illustrated in the accompanying drawings. The drawings are not necessarily to scale; emphasis instead being placed upon illustrating the principles of various embodiments of the present disclosure.
The details of one or more embodiments of the present disclosure are set forth in the accompanying description below. Although any materials and methods similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred materials and methods are now described. Other features, objects and advantages of the present disclosure will be apparent from the description. In the description, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. In the case of conflict, the present description will control.
Langerhans cells (LC) are a unique population of mononuclear phagocytes that are seeded from common macrophage precursors in the skin epidermis before birth. They are highly conserved across vertebrate species and this, with their location at the interface with the environment, suggests the strategic importance of LC as immune sentinels at the skin barrier surface.
It was commonly believed that secondary lymphoid organs were the center of T cell immunity, assuming that instructions given during the priming of naïve T cells by migratory and resident dendritic cells (DC) were sufficient for differentiation and effector function by T cells recruited to peripheral sites of tissue injury. However, the field is beginning to appreciate importance of the tissue environment in regulating effector and regulatory T cell function, and it is clear that antigen-presenting cell-T cell interactions play a key role in T cell survival and function outside lymphoid organs. Despite sharing an origin with other tissue-resident macrophages, differentiation of LC is associated with the acquisition of DC-like functions, namely the ability to migrate to skin-draining lymph nodes (LN) and interact with naïve T cells.
The present disclosure provides methods for the treatment of Langerhans cell sarcoma (LCS) and Langerhans cell histiocytosis (LCH) comprising administering to a subject or patient in need thereof, a therapeutically effective amount of a HDAC3 inhibitor.
Langerhans cell sarcoma (LCS) is a neoplastic proliferation of Langerhans cells with notably malignant cytological features.
Langerhans cell histiocytosis (LCH) is a disease characterized by clonal expansion of myeloid precursors that differentiate into CD1a/CD207 (Langerhans cells) in lesions.
Langerhans cell histiocytosis (LCH) is a disorder that primarily affects children, but is also found in adults of all ages. People with LCH produce too many Langerhans cells or histiocytes, a form of white blood cell found in healthy people that is supposed to protect the body from infection. In people with LCH, these cells multiply excessively and build up in certain areas of the body, causing tumors called granulomas to form. The symptoms of LCH vary from person to person, depending on the areas of the body affected. LCH may be found in many areas of the body, including but not limited to the skin and nails, mouth, bones, lungs, liver, spleen, bone marrow, lymph nodes, pituitary gland, and thyroid gland. When it is found in multiple areas of the body, it is known as multisystem disease. The cause of this disease is unknown, although most data suggest that it is characterized by a hyperproliferative growth of immature Langerhans cells.
Certain symptoms or combination of symptoms may be used to diagnose LCH and/or LCS, which include, but not limited to the following: Skin: (Rashes that may be scaly or waxy, Hair loss, and crusty or oily patches on the scalp (may be misdiagnosed as cradle cap); Bone (Bone pain, lumps or lesions on the skull, upper or lower limbs, hands or feet, ribs, pelvis and spine); Stomach (pain in the abdomen or pelvis, yellow skin, vomiting, diarrhea, blood in stool); Liver/spleen (enlarged liver or belly, abnormal blood tests); Lungs (chest pain, problems breathing or shortness of breath, and cough); Brain or Central Nervous System (headaches, dizziness, seizures, blurred or loss of vision, bulging eyeballs, problems swallowing or speaking); Mouth (mouth ulcers, swollen or bleeding gums, swollen lymph nodes in neck); Ears (loss of hearing, discharge from ear canal, redness, and cysts).
High-risk LCH generally involves multiple organs including the liver, bone marrow or spleen. For children with high-risk LCH, the best treatment is chemotherapy (chemo) that lasts about a year.
In some embodiments, the first-line therapy involves a regiment of chemotherapy. Chemotherapy (“chemo”)—uses powerful medicines to kill cells or stop them from growing (dividing) and making more cells. Combination therapy uses more than one type of chemo at a time.
If Langerhans cell histiocytosis is affecting more than one part of the body, the treatment plan. Will likely involve chemotherapy if medical personnel find the disease on the skin and the liver, or find multiple bone lesions.
The standard treatment for Langerhans cell histiocytosis is the use of a combination of chemotherapy drugs. Because chemotherapy treatment doesn't work for everyone, another first-line therapy includes oral administration of an oral drug (either dabrafenib or trametinib) that blocks certain BRAF gene mutations that is associated with Langerhans cell histiocytosis. This “BRAF gene inhibitor” therapy, has been successful in many pediatric patients. It does not cause the side effects of chemotherapy.
Methods of the present disclosure have been based in part on the finding that HDAC3 serves as a key epigenetic regulator that differentially affects Langerhans Cells (LC) development, homeostasis, repopulation, and disease. HDAC3 could be a therapeutic target in Langerhans cell sarcoma and Langerhans cell Histiocytosis.
HDAC inhibitors have been approved by FDA to treat Cutaneous T-cell lymphoma (CTCL) and myeloma. The present disclosure provides for novel methods using HDAC3 inhibitors for treating Langerhans cell sarcoma and Langerhans cell histiocytosis.
Langerhans cell sarcoma (LCS) is a neoplastic proliferation of Langerhans cells with notably malignant cytological features.
Langerhans cell histiocytosis (LCH) is a disease characterized by clonal expansion of myeloid precursors that differentiate into CD1a/CD207 (Langerhans cells) in lesions.
The present disclosure provides a method for treating, preventing or ameliorating the symptoms of Langerhans cell histiocytosis (LCH) or Langerhans cell sarcoma (LCS) in a subject in need thereof, the method comprising administering a therapeutically effective HDAC3 inhibitor to the subject. In various embodiments, HDAC3 inhibitor is a selective inhibitor that inhibits class I HDAC enzymes in a mammal, for example, a human HDAC1, HDAC2 and HDAC3 HDAC. In various embodiments, the HDAC3 inhibitor is a selective inhibitor that predominantly inhibits HDAC3, relative to other class I HDAC species, and other non-class I HDAC species.
The selective HDAC3 inhibitor useful in the methods of the present disclosure is more (e.g., at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold more) active for inhibiting HDAC3 than for inhibiting a histone deacetylase that is not HDAC3. In certain embodiments, the selective HDAC3 inhibitor is more active in an in vitro enzymatic inhibition assay for inhibiting HDAC3 than for inhibiting a histone deacetylase that is not HDAC3.
Examples of HDAC3 inhibitors useful in the present disclosure include: Mocetinostat (MGCD0103), CUDC-101, Quisinostat (JNJ-26481585) 2HCI, Pracinostat (SB939), Droxinostat, Abexinostat (PCI-24781), Entinostat, Fimepinostat (CUDC-907), RG2833 (RGFP109), RGFP966, BRD3308, SR-4370, TC-H 106, U1F010, Tucidinostat (Chidamide), Citarinostat (ACY-241), Domatinostat (4SC-202), and HPOB. Other HDAC3 inhibitors for example selective HDAC3 inhibitors useful in the present disclosure are known in the art, and may also include those described in following US Patent references: U.S. Pat. Nos. 10,125,131, 9,562,013, 9,139,583, and 9,096,549, and U.S. patent application Ser. No. 16/246,320, filed Jan. 11, 2019, Ser. No. 15/389,838, filed Dec. 23, 2016, Ser. No. 14/753,913, filed Jun. 29, 2015, Ser. No. 14/169,775, filed Jan. 31, 2014, Ser. No. 14/169,732, filed Jan. 31, 2014, the disclosures of all of the preceding patent references are incorporated by reference herein in their entireties.
In another aspect, the invention provides a pharmaceutical composition comprising a selective HDAC3 inhibitor described herein or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier. In various embodiments, HDAC3 inhibitors of the present invention, may be HDAC3 inhibitors that also may inhibit, other HDAC species such as HDACC1, HDAC2 and HDAC8, but in general, are more selective against HDAC3 than other HDAC isoforms. In some embodiments, the present disclosure provides the use of selective HDAC3 inhibitors for the treatment, prevention and amelioration of symptoms associated with LCH and LCS. In one aspect, the invention provides compounds that possess thermodynamic and kinetic binding selectivity for HDAC3 over HDAC1 and HDAC2 and HDACs 4, 5, 6, 7, 8 and 9. While there are HDAC inhibitors in the clinic, most of these do not show significant selectivity for an individual HDAC isoform. Non-selective HDAC inhibitors may be associated with adverse effects. For example, some non-selective inhibitors are believed to be associated with undesirable hematological side effects, such as anemia and thrombocytopenia (loss of platelets). Other adverse side effects related to non-selective HDAC inhibition include fatigue, anorexia, and GI-toxicity. In certain embodiments, the HDAC3 inhibitor reduces the activity of one histone deacetylase (e.g., HDAC3) or a sub-group of histone deacetylases (e.g., HDAC1, HDAC2, and HDAC3) to a greater extent than other histone deacetylases. Where the compound preferentially reduces the activity of a sub-group of histone deacetylases, the reduction in activity of each member of the sub-group may be the same or different.
In certain embodiments, the present invention relates to the aforementioned HDAC3 inhibitor. In one aspect, a HDAC3 inhibitor is a selective HDAC3 inhibitor. In another embodiment, the HDAC3 inhibitor is a HDAC1, 2, 3 selective inhibitor.
In one embodiment, a HDAC3 inhibitor is selective for HDAC3, and will have at least about 1-fold, or 2-fold (e.g., at least about 5-fold, 10-fold, 15-fold, or 20-fold) greater activity to inhibit HDAC3 as compared to one or more other HDACs (e.g., one or more HDACs of class I or II, one or more of HDAC1 and HDAC2).
In one aspect, a compound of the invention possesses thermodynamic and kinetic binding selectivity for HDAC3 over HDAC1 and HDAC2. Long residence times are advantageous in terms of duration of pharmacological effect and target selectivity. Long residence times can also mitigate off-target toxicity (Copeland, R. A. et al., Nature, 5, 730-739 (2006); Copeland, R. A. et al., Future Med. Chem. 3(12), 1491-1501 (2011)).
In one embodiment, a HDAC3 inhibitor, for example, a selective HDAC3 inhibitor selectively inhibits at least one, class I HDAC enzymes with an IC50 value greater than 0.0000001 μM and less than or equal to 0.1 μM, 1 μM, 5 μM, 20 μM, 30 μM, 50 μM, or 75 μM. In another embodiment, a HDAC3 inhibitor selectively inhibits at least two, class I HDAC enzymes with an IC50 value greater than 0.0000001 μM and less than or equal to 0.1 μM, 1 μM, 5 μM, 20 μM, 30 μM, 50 μM, or 75 μM. In one embodiment, a HDAC3 inhibitor, for example, a selective HDAC3 inhibitor selectively inhibits HDAC3 enzyme in a human subject, or equivalent thereof, with an IC50 value greater than 0.0000001 μM and less than or equal to 0.1 μM, 1 μM, 5 μM, 20 μM, 30 μM, 50 μM, or 75 μM. In another embodiment, a compound selectively inhibits an HDAC3 enzyme, with an IC50 value greater than 0.0000001 μM and less than or equal to 0.1 μM, 1 μM, 5 μM, 20 μM, 30 μM, 50 μM, or 75 μM. In one embodiment, the invention provides a method of treating, alleviating, and/or preventing LCH or LCS in a subject, for example a human subject, the method comprising administering to the subject in need thereof an effective amount of a HDAC3 inhibitor, for example, a selective HDAC3 inhibitor of the invention or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof.
The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a HDAC3 inhibitor, for example, a selective HDAC3 inhibitor of the present invention formulated together with one or more pharmaceutically acceptable carriers. The term “pharmaceutically acceptable carrier” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray.
Selective HDAC3 inhibitor compounds of the invention can be administered as pharmaceutical compositions by any conventional route, in particular enterally, e.g., orally, e.g., in the form of tablets or capsules, or parenterally, e.g., in the form of injectable solutions or suspensions, topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form. Pharmaceutical compositions comprising a selective HDAC3 inhibitor compound of the present invention in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable excipient, carrier or diluent can be manufactured in a conventional manner by mixing, granulating or coating methods. For example, oral compositions can be tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Injectable compositions can be aqueous isotonic solutions or suspensions, and suppositories can be prepared from fatty emulsions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Suitable formulations for transdermal applications include an effective amount of a compound of the present invention with a carrier. A carrier can include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin. Matrix transdermal formulations may also be used. Suitable formulations for topical application, e.g., to the skin and eyes, are preferably aqueous solutions, ointments, creams or gels well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
The HDAC3 inhibitor, for example, a selective HDAC3 inhibitor compound can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
In certain embodiments, the subject is identified as in need of such treatment for Langerhans cell sarcoma (LCS) and Langerhans cell histiocytosis (LCH) is administered a therapeutically effective amount of a HDAC3 inhibitor, for example, a selective HDAC3 inhibitor, or a pharmaceutical composition comprising a HDAC3 inhibitor, for example, a selective HDAC3 inhibitor, to a subject in need thereof, in such amounts and for such time as is necessary to achieve the desired result. In certain embodiments of the present invention, a “therapeutically effective amount” of the selective HDAC3 inhibitor or pharmaceutical composition is that amount effective for reducing or eliminating the growth of the histiocytes, or Langerhans cells involved in LCS or LCH. The HDAC3 inhibitors and compositions, according to the methods of the present disclosure, can be administered using any amount, and any route of administration effective for reducing or eliminating the growth of the histiocytes, or Langerhans cells involved in LCS or LCH. Thus, the expression “amount effective to reduce or eliminate the growth of the histiocytes, or Langerhans cells involved in LCS or LCH” as used herein, refers to a sufficient amount of a HDAC3 inhibitor, for example, a selective HDAC3 inhibitor to inhibit the growth of said histiocytes or Langerhans cells involved in the pathology of LCH and LCS. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular anticancer agent, its mode of administration, and the like.
In some embodiments, the method is a method of inhibiting (e.g., by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or about 100%) proliferation of LCS and LCH, or inducing death (e.g., by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or about 100%) of LCS or LCH in a subject, the method comprising administering a selective HDAC3 inhibitor as described herein, to a subject in need thereof as described herein, e.g., a subject having LCS or LCH, or predisposed for developing LCH or LCS. In some embodiments, the selective HDAC3 inhibitor and the MAPK inhibitor, and/or immunotherapy and/or chemotherapy agent(s) act synergistically to treat LCH or LCS compared to the HDAC3 inhibitor used alone.
In various embodiments, selective HDAC3 inhibitors are administered in therapeutically effective doses to treat LCS or LCH in a subject in need thereof.
The treatment regimens and pharmaceutical compositions described herein can be administered intravenously, subcutaneously, topically, orally, or by any other route described herein. In one approach, a loading-dose of a HDAC3 inhibitor, for example, a selective HDAC3 inhibitor is administered to a subject in need thereof, followed by maintenance dosing administered orally.
In various embodiments, HDAC3 inhibitors useful in the methods of the present disclosure as provided herein, for use as a single agent or for use in a combination treatment modality, with a MAPK inhibitor, for example, a BRAF inhibitor, an AKT inhibitor or a MEK inhibitor or a chemotherapeutic agent, (for example, including but not limited to cytarabine, vinblastine, cyclophosphamide, thalidomide, and leucovorin) can include one or more of the following HDAC3 inhibitors: Mocetinostat (MGCD0103), CUDC-101, Quisinostat (JNJ-26481585) 2HCI, Pracinostat (SB939), Droxinostat, Abexinostat (PCI-24781), Entinostat, Fimepinostat (CUDC-907), RG2833 (RGFP109), RGFP966, BRD3308, SR-4370, TC-H 106, U1F010, Tucidinostat (Chidamide), Citarinostat (ACY-241), Domatinostat (4SC-202), and HPOB. Other selective HDAC3 inhibitors useful in the present disclosure are known in the art, and may also include those described in following US Patent references: U.S. Pat. Nos. 10,125,131, 9,562,013, 9,139,583, and 9,096,549, and U.S. patent application Ser. No. 16/246,320, filed Jan. 11, 2019, Ser. No. 15/389,838, filed Dec. 23, 2016, Ser. No. 14/753,913, filed Jun. 29, 2015, Ser. No. 14/169,775, filed Jan. 31, 2014, Ser. No. 14/169,732, filed Jan. 31, 2014, the disclosures of all of the preceding patent references are incorporated by reference herein in their entireties.
In various embodiments, methods for the prevention, treatment or amelioration of symptoms associated with LCH or LCS in a subject, for example a mammal, for example a human subject in need thereof, comprises administering a therapeutically effective dose of a HDAC3 inhibitor to the subject. In related embodiments, the HDAC3 inhibitor is selected from: Mocetinostat (MGCD0103), CUDC-101, Quisinostat (JNJ-26481585) 2HCI, Pracinostat (SB939), Droxinostat, Abexinostat (PCI-24781), Entinostat, Fimepinostat (CUDC-907), RG2833 (RGFP109), RGFP966, BRD3308, SR-4370, TC-H 106, U1F010, Tucidinostat (Chidamide), Citarinostat (ACY-241), Domatinostat (4SC-202), and HPOB. In related embodiments, the HDAC3 inhibitor is a selective HDAC3 inhibitor. In related embodiments, the selective HDAC3 inhibitor is RGFP966 ((2E)-N-(2-Amino-4-fluorophenyl)-3-[(2E)-1-(3-phenyl-2-propen-1-yl)-1H-pyrazol-4-yl]-2-propenamide, (E)-N-(2-amino-4-fluorophenyl)-3-(1-cinnamyl-1H-pyrazol-4-yl)acrylamide, CAS No. 1396841-57-8), having the structure:
or a pharmaceutically acceptable salt thereof. RGFP966 is commercially available from Selleckchem, Catalog No. S7229; Radnor, PA, USA. In some embodiments, the present disclosure provides the use of a HDAC3 inhibitor for the manufacture of a medicament for preventing or treating LCH or LCS in a subject comprising administering an effective or therapeutically effective dose to the subject that results in the prevention or treatment of LCH or LCS. In other embodiments, the present disclosure provides use of a HDAC3 inhibitor for the prevention or treatment of LCH or LCS, comprising administering an effective or therapeutically effective dose to the subject that results in the prevention or treatment of LCH or LCS. In related embodiments, the HDAC3 inhibitor as mentioned in all of the methods above comprises one or more selective HDAC3 inhibitors. In related embodiments, the HDAC3 inhibitor is selected from: Mocetinostat (MGCD0103), CUDC-101, Quisinostat (JNJ-26481585) 2HCI, Pracinostat (SB939), Droxinostat, Abexinostat (PCI-24781), Entinostat, Fimepinostat (CUDC-907), RG2833 (RGFP109), RGFP966, BRD3308, SR-4370, TC-H 106, UF010, Tucidinostat (Chidamide), Citarinostat (ACY-241), Domatinostat (4SC-202), and HPOB. In related embodiments, the HDAC3 inhibitor is a selective HDAC3 inhibitor. In related embodiments, the selective HDAC3 inhibitor is RGFP966 ((2E)-N-(2-Amino-4-fluorophenyl)-3-[(2E)-1-(3-phenyl-2-propen-1-yl)-1H-pyrazol-4-yl]-2-propenamide, (E)-N-(2-amino-4-fluorophenyl)-3-(1-cinnamyl-1H-pyrazol-4-yl)acrylamide, CAS No. 1396841-57-8). In another embodiment, illustrative selective HDAC3 inhibitors useful in the present methods and compositions include HDAC3 inhibitors described in Jian Liu, et al., Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group, ACS Medicinal Chemistry Letters 2020 11 (12), 2476-2483, the disclosure of which is incorporated herein by reference in its entirety.
In general, selective HDAC3 inhibitor compounds of the invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents. Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's LCH or LCS disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity. Optimal doses are generally determined using experimental models and/or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient.
In general, effective or therapeutically effective doses of any of the HDAC3 inhibitors described herein to be obtained systemically at daily dosages ranging from about 0.01 to 1,000 mg/kg or from about 1 mg/kg to about 200 mg/kg per body weight, for any of the methods described in the present application for the treatment, prevention and amelioration of symptoms associated with LCH or LCS. An indicated daily dosage in an exemplary larger mammal, e.g. humans, is in the range from about 0.5 mg to about 1000 mg per dose, or per daily dose, or per weekly dose, conveniently administered, e.g. in divided doses up from one to four times a day or in retard form. Suitable unit dosage forms for oral administration comprise from ca. 1 to 500 mg of the HDAC3 inhibitor, for example, a selective HDAC3 inhibitor.
In certain embodiments, a therapeutic amount or effective dose, or effective daily dose, or effective weekly dose of the HDAC3 inhibitor, for example, a selective HDAC3 inhibitor of the present disclosure, may range from about 0.001 mg/kg to about 500 mg/kg (about 0.018 mg/m2 to about 900 mg/m2), alternatively from about 0.1 mg/kg to about 100 mg/kg (about 0.18 to about 180 mg/m2). In some embodiments, therapeutically effective dose, or therapeutically effective daily dose or therapeutically effective weekly dose, can include an amount ranging from about 10 mg to about 300 mg, dosed, once or more per day, for two or more days per week, for at least one to 30 weeks per regimen. In some embodiments, the HDAC3 inhibitor is dosed to a subject with LCH or LCS in doses ranging from about 10 mg-50 mg per dose, administered per oral, two to three times per week, for a duration ranging from about one day to 20 weeks. In alternate embodiments, the HDAC3 inhibitor is dosed to a subject in need thereof, for use in an intravenous, drip, starting from about 5 mg—to about 300 mg per 10 mL, per 100 ml, or per 1,000 mL IV fluid volume (and all mL intervals therein) for one or more doses, per week, once per week, or one or more doses every two weeks, or one or more doses every three weeks, or one or more doses every four weeks. The regimen just described may incorporate effective doses of a HDAC3 inhibitor, therapeutically effective doses of a HDAC3 inhibitor, or sub-therapeutic effective doses of a HDC3 inhibitor, for example, when the HDAC3 inhibitor is coadministered with a secondary active agent as discussed herein.
In general, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the HDAC3 inhibitor, for example, a selective HDAC3 inhibitor of this invention per day in single or multiple doses. Therapeutic amounts or doses will also vary depending on route of administration, as well as the possibility of co-usage with other secondary agents.
Upon improvement of a subject's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. The subject may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
It will be understood, however, that the total daily usage of the selective HDAC3 inhibitor compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific inhibitory dose for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
In various embodiments, the present disclosure provides methods for preventing LCH and LCS, or treating LCH and LCS, or ameliorating symptoms associated with LCH and LCS using a combination of a HDAC3 inhibitor, for example, a selective HDAC3 inhibitor and a secondary active agent selected from, a chemotherapeutic agent, an immunomodulating agent, a MAPK inhibitor or combinations thereof.
In some embodiments, the present disclosure provides a method for the prevention of LCH or LCS, treatment of LCH or LCS, or amelioration of symptoms associated with LCH or LCS in a subject, for example a mammal, for example a human subject in need thereof, the method comprises administering a therapeutically effective combination comprising a HDAC3 inhibitor and a secondary active agent, wherein the secondary active agent is a MAPK inhibitor, and administering a therapeutically effective dose of the HDAC3 inhibitor or MAPK inhibitor to the subject to prevent LCH or LCS, treat LCH or LCS, or ameliorate the symptoms associated with LCH or LCS.
As used herein, “MAPK inhibitor” includes any agent which inhibits, downregulates or decreases activity of any component of the MAPK signaling pathway, including BRAF, MEK, ERK, etc. See, Nikiforov, Y., Thyroid carcinoma: molecular pathways and therapeutic targets, Modern Pathology, 2008, 21:S37-43, which is incorporated herein by reference. In some embodiments, the MAPK inhibitor is a BRAF inhibitor. In related embodiments, the BRAF inhibitor inhibits and is effective against BRAFV600 mutations, for example, BRAFV600E mutations.
In another embodiment, the MAPK inhibitor is RAF265 (also called CHIR-265). RAF265 is an orally bioavailable small molecule with preclinical antitumor activity that currently is being tested in clinical trials. Much like sorafenib, in vitro kinase assays show RAF265 inhibits the activities of several intracellular kinases, including BRAF (V600E), BRAF (wild type), c-RAF, VEGF receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), colony-stimulating factor (CSF)1R, RET and c-KIT, SRC, STE20, and others with IC50 ranging from less than 20 to more than 100 nmol/L. However, in cell-based assays, RAF265 is most potent for BRAFV600E, and VEGFR2, but less active for PDGFRB and c-KIT. See, Su et al, RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors, Clinical Cancer Research, Apr. 15, 2012, 18:2184, which is incorporated herein by reference. RAF265 has a molecular weight of 518.41 and is available from Selleckchem.com.
In one embodiment, the MAPK inhibitor is PLX4720. In another embodiment, the MAPK inhibitor is PLX4032 (vemurafenib). PLX4720 is a structurally closely related precursor of vemurafenib. In another embodiment, the MAPK inhibitor includes PLX4720 and PLX4032. See, Michaelis et al, Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function, Journal of Pharmacy and Pharmaceutical Sciences, 2014, 17(1):154-68, which is incorporated herein by reference.
In another embodiment, the MAPK inhibitor is AZD6244 (Selumetinib). Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM in cell-free assays, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38a, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Clinical trials of Selumetinib in patients with BRAFv600E/K-mutated melanoma are ongoing (see, e.g., Catalanotti et al, Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma, Clinical Cancer Research, 2013 Apr. 15; 19(8):2257-64, which is incorporated by reference). AZD6244 has a molecular weight of 457.68 and is available from Selleckchem.com.
In another embodiment, the MAPK inhibitor is PD0325901. A second-generation oral MEK inhibitor, compound PD 0325901 demonstrates relatively minor changes in the chemical structure of PD 0325901 as compared to its predecessor CI-1040. The cyclopropylmethoxy group of CI-1040 was replaced with a (R)-dihydroxy-propoxy group and the 2-chloro substituent of CI-1040 was replaced with a 2-flouro group on the second aromatic ring, resulting in significant increases in potency. See, e.g., Wang et al, 2007, cited above.
In another embodiment, the MAPK inhibitor is LGX818 (encorafenib). Encorafenib is a novel oral small molecule kinase inhibitor with potent and selective inhibitory activity against mutant BRAF kinase. LGX818 is currently in phase 3 clinical trials for treatment of BRAF V600 mutant melanoma. LGX818 has a molecular weight of 540.01 and is property of Novartis.
In another embodiment, the MAPK inhibitor is MEK162 (binimetinib). MEK162 is a highly selective, orally bioavailable, ATP-uncompetitive inhibitor of MEK1/2. In previous preclinical work, MEK162 was found to be highly effective in inhibiting growth of xenograft tumors regardless of Ras/Raf pathway deregulation. MEK162 is currently in clinical trials for patients with RAS/RAF/MEK activated tumors. See, Ascierto et al, MEK162 for patients with advanced melanoma harboring NRAS or Val600 BRAF mutations (also referred to as BRAFV600E) or: a non-randomized, open-label phase 2 study, Lancet Oncology, 2013 March; 14(3):249-56, which is incorporated herein by reference. MEK162 has a molecular weight of 441.23 and is property of Novartis.
In another embodiment, the MAPK inhibitor is dabrafenib. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF (V600)-mutated metastatic melanoma. Dabrafenib was approved as a single agent treatment for patients with BRAF V600E mutation-positive advanced melanoma on May 30, 2013. Clinical trial data demonstrated that resistance to dabrafinib and trametinib occurs within 6 to 7 months. To overcome this resistance, the BRAF inhibitor dabrafenib was combined with the MEK inhibitor trametinib. On Jan. 8, 2014, the FDA approved the combination of dabrafenib and trametinib for the treatment of patients with BRAF V600E/K-mutant metastatic melanoma. Thus, in on embodiment, the MAPK inhibitor includes dabrafenib and trametinib. In another embodiment, the MAPK inhibitor is trametinib.
In another embodiment, the MAPK inhibitor includes more than one agent. In one embodiment, the MAPK inhibitor includes PLX4720 and PD0325901. In another embodiment, the MAPK inhibitor includes dabrafenib and trametinib. In yet another embodiment, the MAPK inhibitor includes LGX818 and MEK162.
As used herein, “MAPK inhibitor” includes the specific MAPK inhibitor compounds described herein, and salts derived from pharmaceutically or physiologically acceptable acids, bases, alkali metals and alkaline earth metals. Physiologically acceptable acids include those derived from inorganic and organic acids. A number of inorganic acids are known in the art and include, without limitation, hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric, and phosphoric acid. A number of organic acids are also known in the art and include, without limitation, lactic, formic, acetic, fumaric, citric, propionic, oxalic, succinic, glycolic, glucuronic, maleic, furoic, glutamic, benzoic, anthranilic, salicylic, tartaric, malonic, mallic, phenylacetic, mandelic, embonic, methanesulfonic, ethanesulfonic, panthenoic, benzenesulfonic, toluenesulfonic, stearic, sulfanilic, alginic, and galacturonic acids. In another embodiment, the MAPK inhibitor includes any MAPK inhibitor known in the art or developed hereafter. Physiologically acceptable bases include those derived from inorganic and organic bases. A number of inorganic bases are known in the art and include, without limitation, aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc sulfate or phosphate compounds, among others. Organic bases include, without limitation, N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, and procaine, among others. Physiologically acceptable alkali salts and alkaline earth metal salts include, without limitation, sodium, potassium, calcium and magnesium salts, optionally in the form of esters, and carbamates. The MAPK inhibitor compound salts can be also in the form of esters, carbamates, sulfates, ethers, oximes, carbonates, and other conventional “pro-drug” forms, which, when administered in such form, convert to the active moiety in vivo. In one embodiment, the prodrugs are esters.
The MAPK inhibitor compounds discussed herein also encompasses “metabolites” which are unique products formed by processing the PI3K inhibitor compound by the cell or subject. In one embodiment, metabolites are formed in vivo.
As used herein, the term “effective amount” or “pharmaceutically effective amount” as it refers to individual composition components, refers to the amount of e.g., the selected MAPK inhibitor described herein that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following, preventing a disease; e.g., inhibiting a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting or slowing further development of the pathology and/or symptomatology); ameliorating a disease, condition or disorder, i.e. LCH or LCS in an individual that is experiencing or displaying the pathology or symptomatology of LCH or LCS (i.e., reversing the pathology and/or symptomatology); and inhibiting a physiological process. For example, an effective amount of a combination of a HDAC3 inhibitor, for example, a selective HDAC3 inhibitor and a MAPK inhibitor, for example a BRAF inhibitor, when administered to a subject to treat LCH or LCS, is sufficient to inhibit, slow, reduce, or eliminate tumor growth in a subject having LCH or LCS.
The effective dosage or amount of the second active agent of the combination with a HDAC3 inhibitor, i.e. a MAPK inhibitor may vary depending on the particular compound employed, the mode of administration, the type and severity of the condition being treated, and subject being treated as determined by the subject's physician. The effective dosage of each active component (e.g., a HDAC3 inhibitor and a MAPK inhibitor) is generally individually determined, although the dosages of each of the HDAC3 inhibitor and the MAPK inhibitor can be the same. In one embodiment, the dosage of each of the HDAC3 inhibitor and the MAPK inhibitor in the combination is about 0.001 mg to about 1,000 mg. In one embodiment, the effective amount is or about 0.1 to about 500 mg/kg of body weight, or about 0.1 to about 200 mg/kg of body weight, including any intervening amount. In another embodiment, the effective amount of each of the HDAC3 inhibitor and the MAPK inhibitor in the combination, is about 0.5 to about 40 mg/kg. In a further embodiment, the effective amount of the HDAC3 inhibitor and the MAPK inhibitor is about 0.7 to about 30 mg/kg. In still another embodiment, the effective amount of the HDAC3 inhibitor and the MAPK inhibitor is about 1 to about 20 mg/kg. In yet a further embodiment, the effective amount of each of the HDAC3 inhibitor and the MAPK inhibitor independently is about 0.001 mg/kg to about 1000 mg/kg body weight. In another embodiment, the effective amount of each of the HDAC3 inhibitor and the MAPK inhibitor is less than about 5 g/kg, about 500 mg/kg, about 400 mg/kg, about 300 mg/kg, about 200 mg/kg, about 100 mg/kg, about 50 mg/kg, about 25 mg/kg, about 10 mg/kg, about 1 mg/kg, about 0.5 mg/kg, about 0.25 mg/kg, about 0.1 mg/kg, about 0.075 mg/kg, about 0.05 mg/kg, or about 0.01 mg/kg. However, the effective amount of the MAPK inhibitor compound can be determined by the attending physician and depends on the condition treated, the compound administered, the route of delivery, age, weight, and severity of the patient's symptoms and response pattern of the patient.
Toxicity and therapeutic efficacy of the compounds (HDAC3 inhibitor and/or the MAPK inhibitor, can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. HDAC3 and MAPK inhibitor compounds which exhibit high therapeutic indices are preferred. While HDAC3 and MAPK inhibitor compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue, e.g., bone or cartilage, in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
The data obtained from cell culture assays (such as those described in the examples below) and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
One or more of the combination of HDAC3 and MAPK inhibitor compounds discussed herein may be administered in combination with other pharmaceutical agents, as well as in combination with each other. The term “pharmaceutical” agent as used herein refers to a chemical compound which results in a pharmacological effect in a patient. A “pharmaceutical” agent can include any biological agent, chemical agent, or applied technology which results in a pharmacological effect in the subject.
In addition to the combination of HDAC3 inhibitors with one or more MAPK inhibitor compounds, described above, the HDAC3 inhibitor, for example, a selective HDAC3 inhibitor compound may be combined with a secondary active agent or one or more therapeutic agents which are used to treat solid tumors. In one embodiment, the secondary active agent is a chemotherapeutic. Examples of chemotherapeutic agents include those recited in the “Physician's Desk Reference”, 64th Edition, Thomson Reuters, 2010, which is hereby incorporated by reference. Therapeutically effective amounts of the additional medication(s) or therapeutic agents are well known to those skilled in the art. However, it is well within the attending physician to determine the amount of other medication to be delivered.
In some embodiments, the present disclosure provides a method for the prevention of LCH or LCS, treatment of LCH or LCS, or amelioration of symptoms associated with LCH or LCS in a subject, for example a mammal, for example a human subject in need thereof, the method comprises administering a therapeutically effective combination comprising a HDAC3 inhibitor and one or more secondary active agents, wherein the one or more secondary active agents is one or more chemotherapeutic agents, and administering a therapeutically effective dose of the HDAC3 inhibitor or chemotherapeutic agent(s) to the subject to prevent LCH or LCS, treat LCH or LCS, or ameliorate the symptoms associated with LCH or LCS.
In one embodiment, the chemotherapeutic agent is selected from among cisplatin, carboplatin, 5-fluorouracil, cyclophosphamide, oncovin, vincristine, prednisone, or rituximab, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, carmustine, lomustine, semustine, thriethylenemelamine, triethylene thiophosphoramide, hexamethylmelamine altretamine, busulfan, triazines dacarbazine, methotrexate, trimetrexate, fluorodeoxyuridine, gemcitabine, cytosine arabinoside, 5-azacytidine, 2,2′-difluorodeoxycytidine, 6-mercaptopurine, 6-thioguanine, azathioprine, 2′-deoxycoformycin, erythrohydroxynonyladenine, fludarabine phosphate, 2-chlorodeoxyadenosine, camptothecin, topotecan, irinotecan, paclitaxel, vinblastine, vincristine, vinorelbine, docetaxel, estramustine, estramustine phosphate, etoposide, teniposide, mitoxantrone, mitotane, aminoglutethimide or combinations thereof.
The effective dosage or amount of the secondary active agent of the combination with a HDAC3 inhibitor, i.e. a Chemotherapeutic may vary depending on the particular compound employed, the mode of administration, the type and severity of the condition being treated, and subject being treated as determined by the subject's physician. The effective dosage of each active component (e.g., a HDAC3 inhibitor and a chemotherapeutic agent) is generally individually determined, although the dosages of each active agent can be the same or different. In one embodiment, the dosage of the chemotherapeutic agent is about 0.001 mg to about 1000 mg. In one embodiment, the effective amount chemotherapeutic agent is or about 0.1 to about 500 mg/kg of body weight, or about 0.1 to about 200 mg/kg of body weight, including any intervening amount. In another embodiment, the effective amount of the chemotherapeutic agent in the combination with an HDAC3 inhibitor, is about 0.1 to about 100 mg/kg. In a further embodiment, the effective amount is about 0.7 to about 75 mg/kg. In still another embodiment, the effective amount is about 1 to about 50 mg/kg. In yet a further embodiment, the effective amount of the chemotherapeutic agent is about 0.001 mg/kg to 1,000 mg/kg body weight. In another embodiment, the effective amount of the chemotherapeutic agent for use in the combination with a HDAC3 inhibitor, is less than about 5 g/kg, about 500 mg/kg, about 400 mg/kg, about 300 mg/kg, about 200 mg/kg, about 100 mg/kg, about 50 mg/kg, about 25 mg/kg, about 10 mg/kg, about 1 mg/kg, about 0.5 mg/kg, about 0.25 mg/kg, about 0.1 mg/kg, about 0.075 mg/kg, about 0.05 mg/kg, or about 0.01 mg/kg. However, the effective amount of the chemotherapeutic agent can be determined by the attending physician and depends on the condition treated, the compound administered, the route of delivery, age, weight, and severity of the patient's symptoms and response pattern of the patient.
Toxicity and therapeutic efficacy of the compounds (HDAC3 inhibitor and/or the chemotherapeutic agent, can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. HDAC3 and Chemotherapeutic compounds which exhibit high therapeutic indices are preferred. While HDAC3 and Chemotherapeutic compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue, e.g., bone or cartilage, in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
In some exemplary embodiments, illustrative combinations of HDAC3 inhibitors and secondary active agents for the methods for preventing LCH and LCS, or treating LCH and LCS, or ameliorating symptoms associated with LCH and LCS as disclosed herein comprises a HDAC3 inhibitor, for example, a selective HDAC3 inhibitor and a secondary active agent, wherein the secondary agent is a MAPK inhibitor. In a related embodiment, an illustrative embodiment comprises a combination of a HDAC3 inhibitor, for example a selective HDAC3 inhibitor and BRAF mutation inhibitor. In a related embodiment, an illustrative embodiment comprises a combination of a HDAC3 inhibitor, for example a selective HDAC3 inhibitor and a BRAFV600 mutation inhibitor. In a related embodiment, an illustrative embodiment comprises a combination of a HDAC3 inhibitor, for example a selective HDAC3 inhibitor and a BRAFV600E mutation inhibitor. In a related embodiment, an illustrative embodiment comprises a combination of a HDAC3 inhibitor, for example a selective HDAC3 inhibitor and a MEK inhibitor. In a related embodiment, an illustrative embodiment comprises a combination of a HDAC3 inhibitor, for example a selective HDAC3 inhibitor and Akt1 mutation inhibitor. In an illustrative embodiment comprises a combination of a HDAC3 inhibitor, for example a selective HDAC3 inhibitor and a MKK1/2 inhibitor. In a related embodiment, an illustrative embodiment comprises a combination of a HDAC3 inhibitor, for example a selective HDAC3 inhibitor and MET mutation inhibitor. In a related embodiment, an illustrative combination comprises an HDAC3 inhibitor, for example, a selective HDAC3 inhibitor, and one or more MAPK inhibitors, wherein the one or more MAPK inhibitors is selected from dabrafenib, encorafenib, trametinib, tovorafenib, vemurafenib, PLX4720, GSK2118436 (GSK436), cobimetinib, RAF265 (also called CHIR-265, sorafenib, Tipifarnib, U0126 (EMD Biosciences (662005)), PD184352 (Axon Medchem (1368)), and SB203580 (EMD Biosciences (55389)). In these exemplified combination treatments, the HDAC3 inhibitor is selected from Mocetinostat (MGCD0103), CUDC-101, Quisinostat (JNJ-26481585) 2HCI, Pracinostat (SB939), Droxinostat, Abexinostat (PCI-24781), Entinostat, Fimepinostat (CUDC-907), RG2833 (RGFP109), RGFP966, BRD3308, SR-4370, TC-H 106, UF010, Tucidinostat (Chidamide), Citarinostat (ACY-241), Domatinostat (4SC-202), and HPOB and the one or more MAPK inhibitors is selected from: dabrafenib, encorafenib, trametinib, tovorafenib, vemurafenib, PLX4720, GSK2118436 (GSK436), cobimetinib, RAF265 (also called CHIR-265, sorafenib, Tipifarnib, U0126 (EMD Biosciences (662005)), PD184352 (Axon Medchem (1368)), and SB203580 (EMD Biosciences (55389)). In other embodiments, the combination comprises a HDAC3 inhibitor, and at least one MAPK inhibitor selected from: dabrafenib, encorafenib, trametinib, tovorafenib, vemurafenib, PLX4720, GSK2118436 (GSK436), cobimetinib, RAF265 (also called CHIR-265, sorafenib, Tipifarnib, U0126 (EMD Biosciences (662005)), PD184352 (Axon Medchem (1368)), and SB203580 (EMD Biosciences (55389)). In another embodiment, the combination comprises the selective HDAC3 inhibitor RGFP966, and the MAPK inhibitor is selected from: dabrafenib, encorafenib, trametinib, tovorafenib, vemurafenib, PLX4720, GSK2118436 (GSK436), cobimetinib, RAF265 (also called CHIR-265, sorafenib, Tipifarnib, U0126 (EMD Biosciences (662005)), PD184352 (Axon Medchem (1368)), and SB203580 (EMD Biosciences (55389)). In another example, the combination comprises the selective HDAC3 inhibitor RGFP966, and the one or more MAPK inhibitors is selected from dabrafenib, trametinib, vemurafenib, and PLX4720. In another example, the combination comprises the selective HDAC3 inhibitor RGFP966, and a MAPK inhibitor is selected from: dabrafenib, trametinib, and vemurafenib. In another example, the combination comprises the selective HDAC3 inhibitor RGFP966, and the MAPK inhibitor is dabrafenib. In another example, the combination comprises the selective HDAC3 inhibitor RGFP966, and the MAPK inhibitor is trametinib. In another example, the combination comprises the selective HDAC3 inhibitor RGFP966, and the MAPK inhibitor is vemurafenib. In another example, the combination comprises the selective HDAC3 inhibitor RGFP966, and the MAPK inhibitor is PLX4720. In another example, the combination comprises the selective HDAC3 inhibitor RGFP966, and the one or more MAPK inhibitors are dabrafenib and trametinib.
In other exemplified combination treatments, the HDAC3 inhibitor is selected from Mocetinostat (MGCD0103), CUDC-101, Quisinostat (JNJ-26481585) 2HCI, Pracinostat (SB939), Droxinostat, Abexinostat (PCI-24781), Entinostat, Fimepinostat (CUDC-907), RG2833 (RGFP109), RGFP966, BRD3308, SR-4370, TC-H 106, UF010, Tucidinostat (Chidamide), Citarinostat (ACY-241), Domatinostat (4SC-202), and HPOB and the secondary active agent is a chemotherapeutic agent. In another exemplified example, the In these exemplified combination treatments, the HDAC3 inhibitor is selected from Mocetinostat (MGCD0103), CUDC-101, Quisinostat (JNJ-26481585) 2HCI, Pracinostat (SB939), Droxinostat, Abexinostat (PCI-24781), Entinostat, Fimepinostat (CUDC-907), RG2833 (RGFP109), RGFP966, BRD3308, SR-4370, TC-H 106, UF010, Tucidinostat (Chidamide), Citarinostat (ACY-241), Domatinostat (4SC-202), and HPOB and the one or more chemotherapeutic agents are selected from: cisplatin, carboplatin, 5-fluorouracil, cyclophosphamide, oncovin, vincristine, prednisone, or rituximab, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, carmustine, lomustine, semustine, thriethylenemelamine, triethylene thiophosphoramide, hexamethylmelamine altretamine, busulfan, triazines dacarbazine, methotrexate, trimetrexate, fluorodeoxyuridine, gemcitabine, cytosine arabinoside, 5-azacytidine, 2,2′-difluorodeoxycytidine, 6-mercaptopurine, 6-thioguanine, azathioprine, 2′-deoxycoformycin, erythrohydroxynonyladenine, fludarabine phosphate, 2-chlorodeoxyadenosine, camptothecin, topotecan, irinotecan, paclitaxel, vinblastine, vincristine, vinorelbine, docetaxel, estramustine, estramustine phosphate, etoposide, teniposide, mitoxantrone, mitotane, aminoglutethimide or combinations thereof. In further examples the HDAC3 inhibitor is a selective HDAC3 inhibitor, and the one or more chemotherapeutic agents are selected from: cisplatin, carboplatin, 5-fluorouracil, cyclophosphamide, oncovin, vincristine, prednisone, or rituximab, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, carmustine, lomustine, semustine, thriethylenemelamine, triethylene thiophosphoramide, hexamethylmelamine altretamine, busulfan, triazines dacarbazine, methotrexate, trimetrexate, fluorodeoxyuridine, gemcitabine, cytosine arabinoside, 5-azacytidine, 2,2′-difluorodeoxycytidine, 6-mercaptopurine, 6-thioguanine, azathioprine, 2′-deoxycoformycin, erythrohydroxynonyladenine, fludarabine phosphate, 2-chlorodeoxyadenosine, camptothecin, topotecan, irinotecan, paclitaxel, vinblastine, vincristine, vinorelbine, docetaxel, estramustine, estramustine phosphate, etoposide, teniposide, mitoxantrone, mitotane, aminoglutethimide or combinations thereof. In another illustrative embodiment, the combination comprises a therapeutically effective dose of a selective HDAC3 inhibitor, for example, RGFP966, and the one or more chemotherapeutic agents are selected from: cisplatin, carboplatin, 5-fluorouracil, cyclophosphamide, oncovin, vincristine, prednisone, or rituximab, mechlorethamine, ifosfamide, melphalan, chlorambucil, carmustine, lomustine, semustine, thriethylenemelamine, triethylene thiophosphoramide, hexamethylmelamine altretamine, busulfan, triazines dacarbazine, methotrexate, trimetrexate, fluorodeoxyuridine, gemcitabine, cytosine arabinoside, 5-azacytidine, 2,2′-difluorodeoxycytidine, 6-mercaptopurine, 6-thioguanine, azathioprine, 2′-deoxycoformycin, erythrohydroxynonyladenine, fludarabine phosphate, 2-chlorodeoxyadenosine, camptothecin, topotecan, irinotecan, paclitaxel, vinblastine, vincristine, vinorelbine, docetaxel, estramustine, estramustine phosphate, etoposide, teniposide, mitoxantrone, mitotane, aminoglutethimide or combinations thereof. In some embodiments, the combination comprises therapeutically effective doses of RGFP966, and the one or more chemotherapeutic agents selected from: vincristine, cyclophosphamide, and methotrexate.
In each of the foregoing combinations, the dose of the HDAC3 inhibitor is a therapeutically or effective dose, and the dose of the secondary agent is a therapeutically or effective dose. In some embodiments, the HDAC3 inhibitor is dosed and administered to a subject with LCH or LCS or is likely to develop LCH or LCS in accordance with a prior determined therapeutic regimen as determined in a clinical trial for the treatment of cancer, neurological disease or cardiovascular disease. Similarly, the dose of the secondary active agent, for example, a chemotherapeutic agent, an immunomodulating agent, a MAPK inhibitor or combinations thereof, is a therapeutically or effective dose, as previously deemed therapeutically active and safe in accordance with a prior determined therapeutic regimen as determined in a clinical trial for the treatment of cancer.
At various places in the present specification, features or functions of the compositions of the present disclosure are disclosed in groups or in ranges. It is specifically intended that the present disclosure include each and every individual sub combination of the members of such groups and ranges.
As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100 of a possible value).
As used herein, the terms “associated with,” “conjugated,” “linked,” “attached,” and “tethered,” when used with respect to two or more moieties, mean that the moieties are physically associated or connected with one another, either directly or via one or more additional moieties that serve as linking agents, to form a structure that is sufficiently stable so that the moieties remain physically associated under the conditions in which the structure is used, e.g., physiological conditions. An “association” need not be strictly through direct covalent chemical bonding. It may also suggest ionic or hydrogen bonding or a hybridization-based connectivity sufficiently stable such that the “associated” entities remain physically associated.
The term “cancer” as used herein refers a broad group of various diseases characterized by the uncontrolled proliferation of abnormal cells in the body. Unregulated cell division and growth results in the formation of malignant tumors that invade neighboring tissues, which can ultimately metastasize to distant parts of the body through the lymphatic system or bloodstream.
The term “co-stimulating molecule” as used herein refers to a group of immune cell surface receptor/ligands and soluble molecules, which engage T cells and APCs. T cell stimulatory signals enhance the T cell response to receptor (TCR) recognition of antigen/MIC complex (pMHC) on APCs, and APC stimulatory molecule may induce differentiation or the expression or secretion of immunity priming molecules.
The term “cytokines”, as used herein, refers to a family of small soluble factors with pleiotropic functions that are produced by many cell types that can influence and regulate the function of the immune system.
The term “delivery” as used herein refers to the act or manner of delivering a compound, substance, entity, moiety, cargo or payload. A “delivery agent” refers to any agent which facilitates, at least in part, the in vivo delivery of one or more substances (including, but not limited to a compound and/or composition of the present disclosure) to a cell, subject or other biological system cells.
As used herein, the term “feature” refers to a characteristic, a property, or a distinctive element.
As used herein, the term “formulation” includes at least a compound and/or composition of the present disclosure and a delivery agent.
As used herein, the term “in vitro” refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than within an organism (e.g., animal, plant, or microbe).
As used herein, the term “in vivo” refers to events that occur within an organism (e.g., animal, plant, or microbe or cell or tissue thereof).
The term “pharmaceutically acceptable excipient,” as used herein, refers to any ingredient other than active agents (e.g., as described herein) present in pharmaceutical compositions and having the properties of being substantially nontoxic and non-inflammatory in subjects. In some embodiments, pharmaceutically acceptable excipients are vehicles capable of suspending and/or dissolving active agents. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, and waters of hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.
Pharmaceutically acceptable salts of the compounds described herein are forms of the disclosed compounds wherein the acid or base moiety is in its salt form (e.g., as generated by reacting a free base group with a suitable organic acid). Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Pharmaceutically acceptable salts include the conventional non-toxic salts, for example, from non-toxic inorganic or organic acids. In some embodiments, a pharmaceutically acceptable salt is prepared from a parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, Pharmaceutical Salts: Properties, Selection, and Use, P. H. Stahl and C. G. Wermuth (eds.), Wiley-VCH, 2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19 (1977), each of which is incorporated herein by reference in its entirety. Pharmaceutically acceptable solvate: The term “pharmaceutically acceptable solvate,” as used herein, refers to a crystalline form of a compound wherein molecules of a suitable solvent are incorporated in the crystal lattice. For example, solvates may be prepared by crystallization, recrystallization, or precipitation from a solution that includes organic solvents, water, or a mixture thereof. Examples of suitable solvents are ethanol, water (for example, mono-, di-, and tri-hydrates), N-methylpyrrolidinone (NMP), dimethyl sulfoxide (DMSO), N, N′-dimethylformamide (DMF), N, N′-dimethylacetamide (DMAC), 1,3-dimethyl-2-imidazolidinone (DMEU), 1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (DMPU), acetonitrile (ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone, benzyl benzoate, and the like. When water is the solvent, the solvate is referred to as a “hydrate.” In some embodiments, the solvent incorporated into a solvate is of a type or at a level that is physiologically tolerable to an organism to which the solvate is administered (e.g., in a unit dosage form of a pharmaceutical composition).
As used herein, the term “subject” or “patient” refers to any organism to which a composition in accordance with the disclosure may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and/or plants.
As used herein, the term “therapeutically effective amount” means an amount of an agent to be delivered (e.g., nucleic acid, drug, therapeutic agent, diagnostic agent, prophylactic agent, etc.) that is sufficient, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and/or condition, to treat, improve symptoms of, diagnose, prevent, and/or delay the onset of the infection, disease, disorder, and/or condition. In some embodiments, a therapeutically effective amount is provided in a single dose. In some embodiments, a therapeutically effective amount is administered in a dosage regimen comprising a plurality of doses. Those skilled in the art will appreciate that in some embodiments, a unit dosage form may be considered to comprise a therapeutically effective amount of a particular agent or entity if it comprises an amount that is effective when administered as part of such a dosage regimen.
As used herein, the terms “treatment” or “treating” denote an approach for obtaining a beneficial or desired result including and preferably a beneficial or desired clinical result. Such beneficial or desired clinical results include, but are not limited to, one or more of the following: reducing the proliferation of (or destroying) LCH and LCS cells, shrinking the size of the lresions containing the LCH and LCS or precursors thereof, decreasing symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, delaying the progression of the disease, and/or prolonging survival of individuals.
Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments in accordance with the disclosure described herein. The scope of the present disclosure is not intended to be limited to the above Description, but rather is as set forth in the appended claims.
In the claims, articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The disclosure includes embodiments in which more than one, or the entire group members are present in, employed in or otherwise relevant to a given product or process.
It is also noted that the term “comprising” is intended to be open and permits but does not require the inclusion of additional elements or steps. When the term “comprising” is used herein, the term “consisting of” is thus also encompassed and disclosed.
Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges in different embodiments of the disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
In addition, it is to be understood that any particular embodiment of the present disclosure that falls within the prior art may be explicitly excluded from any one or more of the claims. Since such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the compositions of the disclosure (e.g., therapeutic or active ingredient; any method of use; etc.) can be excluded from any one or more claims, for any reason, whether or not related to the existence of prior art.
It is to be understood that the words which have been used are words of description rather than limitation, and that changes may be made within the purview of the appended claims without departing from the true scope and spirit of the disclosure in its broader aspects.
While the present disclosure has been described at some length and with some particularity with respect to the several described embodiments, it is not intended that it should be limited to any such particulars or embodiments or any particular embodiment, but it is to be construed with references to the appended claims so as to provide the broadest possible interpretation of such claims in view of the prior art and, therefore, to effectively encompass the intended scope of the disclosure. The present disclosure is further illustrated by the following nonlimiting examples.
The role of HDAC3 in LCs precursor differentiation was examined during embryonic development by generating Csf1riCreHdac3fl/fl conditional knockout (cKO) mice, in which HDAC3 is deficient in Csf1r-expressing myeloid cells, including TRMs and monocytes.
HDAC3 mRNA expression was measured in WT and HDAC3 conditional knock-out (Csf1riCreHdac3fl/fl) embryonic and adult mice using quantitative Real-time PCR (qRT-PCR)
The Csf1riCre mouse strain (#021024) was purchased from Jackson Laboratory (Bar Harbor, ME). Hdac3fl/fl mice were provided by Scott W. Hiebert. All transgenic mice were completely viable with a normal Mendelian frequency and backcrossed with C57BL/6 mice for 6 generations for this study. Male and female mice from 6-18 weeks of age were used. All experiments included age- and sex-matched littermate controls. Embryonic stage 0.5 days was estimated from the day of vaginal plug observance.
Mouse embryos were obtained from plug-staged pregnant females sacrificed by CO2 exposure. Embryos ranging from embryonic days E10.5 to E18.5 were removed from the uterus and washed in cold PBS followed by decapitation. The skin samples from embryos at E18.5 and newborn (P0) were treated with dispase II the same as described above for the adult skin preparation. Skin from E10.5 to E16.5 embryos was collected, minced, and incubated at 37° C. for 30 min in PBS containing 3% FBS, 1 mg/ml collagenase D (Roche, Basel, Switzerland), and 0.01% DNase I. The erythrocytes were lysed as described above. All cell suspensions were passed through a 70 μm cell strainer (BD Biosciences, San Jose, CA).
Hdac3fl/fl mice were genotyped by conventional protocols using the following PCR primer pair: forward, SEQ ID NO: 23 (5′-GGA CAC AGT CAT GAC CCG GTC-3′); reverse, SEQ ID NO: 24 (5′-CTC TGG CTT CTG CTA TGT CAA TG-3′). The floxed allele produced a 504-bp PCR product whereas the wild-type (WT) allele resulted in a 464-bp PCR product.
RNA was isolated from the sorted cells with GenElute Total RNA Purification Kit (Sigma Aldrich) and converted to cDNA with High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Foster City, CA). For quantitative PCR, reactions were performed using FastStart Universal SYBR Green Master (ROX, Roche) and carried out using QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems). Data were collected using QuantStudio 7 Flex Real-Time PCR System software version 1.2 (Applied Biosystems) and analyzed using Microsoft Excel 2016 (Microsoft, Redmond, Washington). The full list of primers used in the Examples are shown in Table 1 below. Samples were normalized to β-actin or GAPDH expression.
LC precursor biomarkers were measured in fetal skin by immunolabeling and flow cytometry analysis. The frequency of LC precursors in fetal skin were identified by immunolabeling for F4/80+CD11b+ cell markers and sorting by flow cytometry. The frequency of macrophages in fetal skin were identified by immunolabeling for F4/80hiCD11lo cell markers and sorting by flow cytometry. The frequency of monocytes in fetal skin were identified by immunolabeling for F4/80loCD11bhi cell markers and sorting by flow cytometry.
Biomarkers of Langerhan cells precursors (CD11b and F4/80) in fetal skin were immunolabeled and sorted by flow cytometry. Single-cell suspensions were centrifuged at 450×g for 7 min, resuspended in 4° C. staining buffer (1×PBS containing 2% FBS), and placed in 96-well round-bottom plates. After incubation with purified anti-FcγRII/III antibody (clone 2.4G2) at 4° C. for 15 min, cells were stained at 4° C. for 30 min with a mixture of fluorescent surface antibodies. For intracellular staining, fresh cells with surface staining were fixed with Foxp3/permeabilization buffer (Concentrate: Diluent solution=1:3, eBioscience/Thermo Fisher Scientific) at 4° C. for 25 min and stained with intracellular antibodies in 1× permeabilization buffer (eBioscience/Thermo Fisher Scientific) at 4° C. for 30 min. The full list of antibodies used are shown in Table 2. The stained samples were then acquired on a FACSAria™ II or FACSCelesta™ flow cytometer (BD Biosciences) and data were analyzed using FlowJo 10.5.3 (BD Biosciences). The epidermal CD45+MHC-II+ LCs from adult mice and CD45+F4/80+CD11b+epidermal LC precursors from embryos at E14.5, E16.5, and E18.5 were sorted on a FACSAria™ II flow-cytometer. The purity of the sorted populations was >95%. Spleen CD4+ T cells from OT-II mice were enriched using Dynal® mouse CD4-negative selection kit (Thermo Fisher Scientific) with >85% purity.
The HDAC3 knock-out mouse is completely viable. HDAC3 mRNA expression increases with developmental age and is highest in LC precursors in the adult mouse (
The expression levels of HDAC3 mRNA and protein were robustly reduced (>80%) in LC precursors from the HDAC3 cKO newborns measured by qRT-PCR (
Example 2 examined the level of HDAC3 protein was determined in Hdac3fl/fl and Csf1riCreHdac3fl/fl newborns (P0) by flow cytometry. The level HDAC3 gene and genes related to LC development were determined by sequencing bulk RNA derived from F4/80+CD11b+LC precursors sorted from the fetal epidermis of Hdac3fl/fl and Csf1riCreHdac3fl/fl newborn (P0) pups.
Newborn pups were obtain from the Hdac3fl/fl and Csf1riCreHdac3fl/fl mice described in Example 1. The method of isolating epidermal cells and their detection by immunolabeling and flow cytometry was performed as described in Example 1. HDAC3 and genes related to LC precursor development (Csf1r, Spi1, and 1134) were quantified by Bulk RNA sequencing.
cDNA synthesis and preamplification of total RNA from the sorted cells were performed using the SMART-Seq v4 Ultra Low Input RNA Kit (Clontech, Mountain View, CA) following a standard protocol as described previously. Briefly, cDNA was pre-amplified, sheered and repaired, and the end-repaired DNA fragments were ligated to adaptors. After DNA cleanup, final library amplification was performed followed by gel purification. Sequencing was performed by the DNA sequencing core at University of Michigan using a 50 bp single end read setup on the Illumina Hiseq 4000 platform.
As expected, HDAC3 protein and gene expression was significantly decreased in Csf1riCreHdac3fl/fl mice compared to Hdac3fl/flmice (
Example 3 examined the differentially expressed gene profile by bulk RNA-seq analysis of LC precursors from the fetal epidermis of Csf1riCreHdac3fl/fl and WT to understand the developmental effects caused by HDAC3 deficiency. The direct downstream targets of HDAC3 were also identified by ChIP-seq analysis from WT mice during LC development.
The mice were obtained as described in Example 1. Fetal epidermis was obtained from E18.5 Hdac3fl/fl and Csf1riCreHdac3fl/fl mice as described in Example 1. LC precursors expressing F4/80+CD11b+ were sorted by flow cytometry as described in Example 1, and the Bulk RNA sequencing was performed as described in Example 2.
ChIP sequencing was performed by first cross-linking HDAC3 to genomic DNA, then shearing the DNA, and immunoprecipitating the HDAC3 bound DNA. The immunoprecipated DNA is then unlinked and amplified for next generation sequencing.
Cell pellets from the sorted LCs (0.72×106 and 1.2×106 cells from pooled mice) from WT adult mice were directly frozen at −80° C. Two biological independent samples were then submitted to EpiGentek (Farmingdale, NY) for ChIP, library preparation, and sequencing. Briefly, the cells were fixed with 1% formaldehyde and chromatin was isolated using a CHROMAFLASH™ Chromatin Extraction Kit. Chromatin was sheared to 100-300 bp fragments using the Episonic2000 Sonicating System. ChIP was performed on the chromatin using an antibody against HDAC3 (Abcam, #ab7030, polyclonal, 1 μg/ChIP), and input DNA (without immunoprecipitation) was used to determine background. After adapter linking, the libraries were amplified using indexed primers followed by purification. Ten nanomolar of each sample library was provided for next generation sequencing on a HiSeq 2500.
The ChIP assay was performed on 4×106 cells from 80-90% confluent XS-106 cell cultures for each immunoprecipitation using an SimpleChIP Plus Enzymatic Chromatin IP kit (Cell Signaling, Danvers, MA, #9005) and 10 μl of anti-Histone H3 antibody (Cell Signaling, #4620, clone D2B12, 10 μl/500 μl 1×ChIP buffer), 2 μg of anti-HDAC3 antibody (Abcam, #ab32369, clone Y415, 2 μg/ml), and 1 μg of rabbit IgG (Abcam, #ab171870, polyclonal, 1 μg/ml) per reaction. DNA-relative enrichment was determined by normalization to the rabbit IgG control background signals. All ChIP experiments were obtained from independent chromatin preparations, and all quantitative real-time PCR reactions were performed in duplicates for each sample on each amplicon. Mouse RPL30 gene (primers from Cell Signaling, #7015) was used as a positive control for DNA quantification. Primers for the ChIP-qPCR are listed in Table 3.
The bulk RNA-Seq data and ChIP-Seq data was integrated to identify genes present in both datasets. The RNA-seq reads were aligned to the mouse GRCm38/mm10 reference genome and expression levels for each sample were quantified and normalized using Biomedical Genomics Workbench 5.0 (QIAGEN, Germantown, MD). Gene ontology (GO) biological process enrichment analysis was performed using DAVID Bioinformatics Resources 6.8. Gene Set Enrichment Analysis (GSEA) was performed using GSEA software 4.0.3. Further pathway analysis was performed using the Ingenuity Pathway Analysis (IPA) (QIAGEN Bioinformatics, version 42012434). Raw ChIP-seq reads were quality checked using the software FastQC version v0.10.1. The quality checked reads were then mapped to the mouse mm9 genome sequence using Bowtie (v1.0.0) and only uniquely mapped reads were retained. Mapping results of each ChIP and the input sample were subjected to ChIP-enriched peak calling using the MACS (v2.1.0). Peak annotation was conducted using ChIPseeker (v1.24.0). The peaks identified (FDR<0.05) simultaneously from LC duplicates were used for further analysis. Venn diagram was created through an online tool (http://bioinformatics.psb.ugent.be/webtools/Venn/).
No statistical method was used to predetermine sample size. All results are displayed as mean±SD or mean±SEM, and two-tailed Student's t-test was used to calculate the P values using GraphPad Prism 8.4.3 software (GraphPad, La Jolla, CA) unless otherwise specified. Statistical significance is displayed as below: N.S., not significant; *P<0.05; **P<0.01; ***P<0.001.
Bulk RNA-seq (three biologically independent samples/group) and ChIP-seq (two biologically independent samples/group) were performed one time. Immunofluorescence, bone marrow chimera, qRT-PCR experiments were performed independently twice with similar results. All other experiments were performed independently at least three times with similar results.
A total of 4,546 differentially expressed genes (FDR<0.05) were identified in the LC precursors from HDAC3 cKO mice compared to WT, including 2,139 down-regulated and 2,407 up-regulated genes, are shown in the heat map (
The ChIP sequencing analysis identified 865 overlapping genes in 2 ChIP-seq samples. The integration of the bulk RNA-seq data with the ChIP-seq identified a total of 145 genes present in both datasets, including 80 down-regulated genes and 65 up-regulated genes in the HDAC3 cKO LC precursors that could be primary targets of HDAC3 transcriptional regulation (see Venn diagram,
The role of HDAC3 in the apoptosis of skin resident macrophages and LC precursors during embryonic development was studied by immunolabeling with annexin V and sorting cells by flow cytometry.
Control and HDAC3-deficient skin and epidermal cell suspensions were obtained from HDAC3fl/fl and Csf1ricreHDAC3fl/fl embryonic day 16.5 (E16.5) and embryonic day 18.5 (E18.5) mice as described in Example 1. Immunolabeling and flow cytometry was performed as described in Example 1.
A flow cytometry analysis showed the frequencies of annexin V+ labeled skin resident macrophage (MF) and LC precursors are comparable in WT and HDAC3 cKO mice at E16.5 and E18.5, which indicates that HDAC3 deficiency does not affect cell apoptosis during LC development, and thus is unlikely to play a role in developmental apoptosis (
The role of HDAC3 in postnatal maintenance of LCs in the epidermis was studied by examining LC precursor biomarkers in HDAC3 deficient LCs. A conditional postnatal HDAC3 cKO was generated by crossing huLangerinCre transgenic mice with loxp-flanked Hdac3fl/fl transgenic mice. The human Langerin transgene is only expressed in LCs and not by other murine Langerin expressing cells (e.g., muLangerin+ dermal DCs). Thus, the huLangerinCreHdac3fl/fl double transgenic selectively reduces HDAC3 gene expression LCs.
Additional conditional knock-outs were made to determine whether HDAC3 regulates the maintenance of fully differentiated LCs in during postnatal development and adult mice at steady state.
huLangerinCre and huLangerinCreER mouse strains were provided by Daniel H. Kaplan, and Hdac3fl/fl mice were provided by Scott W. Hiebert. The genotype of huLangerinCre mice were determined by PCR of genomic DNA using conventional protocols and the following PCR primer pairs: mutant, forward, SEQ ID NO: 33 (5′-GAG GCA AAT GAT TGG CAT TCT AC-3′); mutant, reverse, SEQ ID NO: 34 (5′-CTG GAA AAT TCA AGA AGA GCC T-3′); WT, forward, SEQ ID NO: 35 (5′-GTT GCA GCA AAT TCC AAC CC-3′); WT, reverse, SEQ ID NO:36 (5′-GGC CAG GAG AAA CTA CAA GTC A-3′). The mutant allele produced a 272-bp PCR product whereas the WT allele resulted in a 167-bp PCR product. The mouse strain Cd11cCre (Strain #008068), was purchased from Jackson Laboratory (Bar Harbor, ME). Hdac3fl/fl mice were genotyped as described in Example 1 and crossed with huLangerinCre mice and CD11cCre mice to produce CD11cCreHdac3fl/fl and huLangerinCreHdac3fl/fl double transgenic mice, respectively. The CD11cCreHdac3fl/fl double transgenic mice strongly express Cre during the first week after birth in LCs resulting in the deletion of HDAC3 when LCs undergo a burst of proliferation.
LC-specific tamoxifen inducible HDAC3 cKO mice (huLangerinCreERHdac3fl/fl) were made by crossing the Hdac3fl/fl transgenic mouse with a transgenic mouse expressing Cre under the control of the CD11c promote, huLangerinCreER. Tamoxifen inducible Cre transgenic mice huLangerinCreER were purchased from purchased from Jackson Laboratory (Bar Harbor, ME). The huLangerinCreER mice were crossed with Hdac3fl/fl to generate the huLangerinCreERT2Hdac3fl/fl double transgenic mice. Mice were injected with tamoxifen to induce Cre-mediated excision of Hdac3. Deletion of Hdac3 was confirmed by qRT-PCR.
To visualize the density of epidermal LCs the epidermal sheets of mouse ear were gently peeled off the dermis after overnight treatment in PBS containing 20 mM EDTA (VWR Life Science, Radnor, PA). Separated epidermal sheets were fixed with cold acetone at −20° C. for 15 min, followed by blocking with PBS containing 3% bovine serum albumin (BSA) at room temperature (RT) for 15 min. The blocked sheets were incubated overnight with Alexa Fluor 488-labeled anti-langerin and PE-labeled anti-MHC-II antibodies at 4° C. in the dark, and then mounted under a coverslip with one drop of IMMU-MOUNT mounting medium (Thermo scientific). Specimens were viewed on a LEICA DMIRB microscope (Leica Microsystems, Buffalo Grove, IL) at 20× magnification (
Tamoxifen (TAM, Sigma Aldrich) was dissolved in corn oil (Sigma Aldrich) containing 10% (vol/vol) ethanol (Thermo Fisher Scientific) and was intraperitoneally administered at 50 mg/kg of mouse weight for 5 consecutive days. For ex vivo LC function analysis mice were analyzed or further treated on day 9 after the last dose of TAM treatment. The deletion (>90%) of HDAC3 mRNAs in the epidermal LCs of tamoxifen treated huLangerinCreERHdac3fl/fl mice was confirmed by qRT-PCR.
The HDAC3 mRNA expression was robustly decreased (>80%) in the LCs from huLangerinCreHdac3 fl/fl mice (
A flow cytometry analysis demonstrated that the frequency of MHC II+langerin+epidermal LCs was comparable between CD11cCreHdac3fl/fl KO and WT mice by P6 (
Given that minimal external input of LC precursors occurs after birth in steady state, the loss of LCs caused by HDAC3 deletion could be attributable to increased apoptosis. At postnatal day 6 there was no difference in the frequency of Ki-67+ LCs (
At postnatal day 10 there was no difference in the frequency of Ki-67+ LCs (
Relative HDAC3 mRNA expression as measured by qRT-PCR was significantly reduced in MHCII+CD45+epidermal LCs from huLangerinCreERHdac3 fl/fl mice compared to Hdac3 fl/fl mice 10 days after tamoxifen injection (
Several key genes are required for LC homeostasis, including Csf1r (encoding macrophage colony-stimulating factor 1 receptor, M-CSFR), Spi1 (purine rich box-1, PU.1), Id2 (inhibitor of DNA binding 2), Runx3 (runt related transcription factor 3), Lamtor2 (late endosomal adaptor molecule p14) and Ahr (aryl hydrocarbon receptor). A qRT-PCR analysis confirmed the dramatic reduction in mRNA expression of Csf1r, Spi1, Id2, and Runx3 in the LCs from TAM-treated huLangerinCreERHdac3fl/fl mice compared to their WT counterparts (
Collectively, these results suggest that HDAC3 is required for epidermal LC homeostasis during initial establishment of the LC network as well as steady-state self-renewal. In contrast to its role during embryonic development, HDAC3 regulates cell survival for LC maintenance after birth rather than cell proliferation, likely through direct regulation of two transcription factors ID2 and RUNX3 that are essential for LC homeostasis.
The role of HDAC3 during LC repopulation was examined under inflammatory conditions. During inflammation, short-term LCs (MHC II+langerinlow/neg) derived from circulating Gr-1hi monocytes and long-term LCs (MHC II+langerin+) of BM origin transiently or persistently reconstitute the LC compartment, respectively. In contrast to steady-state LC development and/or maintenance, which depends on PU.1, ID2 and RUNX3, the generation of short-term LCs is ID2 independent, while the generation of BM-derived LCs depends on PU.1-mediated RUNX3 expression. Given the significant loss of ID2 and RUNX3 mRNA expression in HDAC3-deficient LCs, as well as direct binding of HDAC3 to ID2 and Runx3 enhancer regions (
The role of HDAC3 in repopulating LC precursors during the inflammatory skin condition produced by UV radiation was examined in the dorsal skin from Hdac3fl/fl WT and Cd11cCreHDAC3fl/fl KO mice. Mice were ultraviolet-C (UVC) irradiated for 15 minutes and LC repopulation evaluated on days 7 and 21 after UVC exposure (see schematic,
LC-depleting skin inflammation was induced on shaved mouse dorsal skin by exposure to ultraviolet light (UV; wavelength: 254 nm; voltage: 8 W; source distance: 38 cm) for 15 or 30 min. The timepoints for evaluating epidermal LC replenishment depended on different UV exposure times (UV exposure for 15 min was evaluated 1 and 3 weeks; UV exposure for 30 min was evaluated at 3 and 6 weeks).
To exclude the confounding factor of incomplete LC depletion by UVC exposure and to further evaluate the role of HDAC3 during long-term LC repopulation, irradiated B6.SJL mice (CD45.1+) were reconstituted with BM cells from Hdac3fl/fl (WT) or Cd11cCreHDAC3fl/fl KO mice (both CD45.2+). Six weeks after reconstitution, the recipient mice received UVC treatment for 30 min to deplete host LCs. B6.SJL (CD45.1+) mice were lethally irradiated with 550 Rads for 2 times. Donor BM cells were harvested from age- and sex-matched CD45.2+Hdac3fl/fl and Cd11cCreHDAC3fl/fl mice by flushing bones with a syringe containing sterile RPMI 1640 medium. After the lysis of erythrocytes, 100 μl of PBS containing approximately 107 BM cells from either HDAC3fl/fl or Cd11cCreHDAC3fl/fl mice was retroorbitally administered into each irradiated recipient mouse. The recipient mice received further treatment until 6 weeks after reconstitution. The B6.SJL mouse strain (#002014) was purchased from Jackson Laboratory (Bar Harbor, ME).
HDAC3 KOs have reduced RUNX3 expression (
As expected, a flow cytometry analysis showed around 40% of CD45+ cells in the epidermis were LCs (MHC II+) prior to UVC treatment (Day 0) in WT mice, while very few LCs existed in the Cd11cCreHDAC3fl/fl KO mice (
Short-term LCs were distinguished from long-term LCs in these mice by langerin expression in MHC II+ cells. In contrast to the steady state, where nearly all LCs in HDAC3fl/fl (WT) and Cd11cCreHDAC3fl/fl KO mice highly expressed langerin, a significant number of MHC II+langerinlow/neg short-term LCs emerged in the inflamed skin in both groups (
Six weeks after reconstituting irradiated B6.SJL mice (CD45.1+) with BM cells from Hdac3fl/fl (WT) or Cd11cCreHDAC3fl/fl KO mice, the recipient mice received UVC treatment for 30 min to deplete host LCs. Subsequently, the recruitment of donor cells into the epidermis was monitored by flow cytometry for 13 days, 3 weeks and 8 weeks after UVC treatment (treatment schematic,
RUNX3-null mice completely lack LCs in skin epidermis at steady state and RUNX3 drives LC differentiation from BM precursors in vitro. As expected, LC frequency was dramatic reduced in mice lacking RUNX3 compared to WT in young mice (2- to 3-weeks old), and the loss of LCs was even more severe in RUNX3-deficient mature adult mice (6-months old) (
The role of HDAC3 in the LC migration, phagocytosis, and LC-mediated T cell immunity was studied in ex vivo cell culture from cells isolated from adult tamoxifen treated huLangerinCreERHdac3fl/fl mice.
The formulation of TAM and the administration of TAM in mice was performed as described in Example 5 methods.
Murine XS-106 epidermal DC line and NS47 fibroblast cell line were a generous gift from Dr. Akira Takashima (University of Toledo). XS-106 cells were cultured in RPMI 1640 medium (Gibco//Thermo Fisher Scientific, Waltham, MA) supplemented with 2 mM L-glutamine, 10% fetal bovine serum (FBS, Hyclone, San Angelo, TX), 2.5 ng/ml murine recombinant granulocyte-macrophage colony stimulating factor (BioLegend, San Diego, CA), 5% NS47 fibroblast supernatant, and 1% penicillin-streptomycin-amphotericin B (Sigma Aldrich, St. Louis, MO). NS47 fibroblasts were maintained in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% FBS and 1% penicillin-streptomycin-amphotericin B, and subcultured (1:4-1:6 split ratio) using 0.25% trypsin-EDTA (Corning). Cells were maintained in a humidified 5% CO2 atmosphere at 37° C. and subcultured by harvesting floating cells from confluent T-75 culture flasks (Corning Incorporated, Corning NY). NS47 fibroblast supernatant was obtained by maintaining confluent cells in T-75 flasks in a minimal volume of culture medium for 4 days. The supernatant was centrifuged and stored at −80° C. prior to use.
Adult mice were sacrificed by CO2 exposure. Mouse skin was dissociated and incubated at 37° C. for 1 hour in phosphate-buffered saline (PBS), Invitrogen, Carlsbad, CA) containing 0.5% dispase II (Gibco). Epidermal sheets were then separated from dermis, cut into small pieces and digested at 37° C. for 15 min in PBS containing 0.025% trypsin and 0.01% DNase I (Worthington Biochemical Corp., Lakewood, NJ). For LC maturation, phagocytosis, and co-culture experiments, epidermal tissues were digested at 37° C. for 1 hour in the RPMI 1640 medium containing 10% FBS and 0.010% DNase I.
Freshly-separated epidermal cells were cultured in complete RPMI 1640 culture medium containing 10% FBS, 2 mM L-glutamine, 50 μM 2-mercaptoethanol, 0.15% sodium hydrogen carbonate, 1 mM sodium pyruvate, nonessential amino acids, 100 U/ml penicillin and 0.01% streptomycin at 37° C. with 5% CO2 for 66-68 hrs. Cells were then stained with antibodies specific for MHC-II, CD45, CD80 and CD86 for the flow cytometric analysis.
LNs were harvested, minced, and incubated at 37° C. for 15 min in PBS containing 0.01% DNase I. Spleen was collected and ground, and erythrocytes were lysed with 0.83% NH4Cl buffer.
Freshly isolated epidermal cell suspensions were cultured with 0.025% fluorescein isothiocyanate (FITC)-dextran (ThermoFisher Scientific, 40,000 MW) for 45 min at 37° C. or 4° C. After extensive washes with PBS, cells were stained with anti-CD45-APC and anti-MHC-II-PE antibodies. The percentage of FITC+ LCs (CD45.2+MHC-II+) was determined by flow cytometry.
Residing at the outermost skin layer, LCs efficiently ingest and process environmental and self-antigens, which is vital to the induction of immune defense and tolerance. To assess the role of HDAC3 in the phagocytic capacity of LCs, freshly-isolated epidermal cells from Hdac3fl/fl (WT) and huLangerinCreERHDAC3fl/fl KO mice were isolated 9-days post TAM treatment and incubated with FITC-dextran for 45 min at 4° C. (as control) or 37° C. The surface expression of langerin in MHC II+epidermal LCs indicates that the innate immune receptor langerin can interact directly with viruses, bacteria, and fungi, and langerin-mediated LC phagocytosis is critical for host defense against microbial pathogens. Langerin expression in epidermal LCs was markedly increased in TAM-treated huLangerinCreERHDAC3fl/fl KO mice compared to WT mice at 4° C. and 37° C. (
Interestingly, a dramatic decrease in langerin surface expression in WT and KO LCs occurred at 37° C. compared to 4° C., indicating that langerin internalization may facilitate LC antigen uptake. Additionally, the frequencies of FITC-dextran+ LCs from huLangerinCreERHDAC3fl/fl KO mice were significantly higher than WT mice when incubated at 37° C. (
As shown in
The peak (˜2 fold) of LC migration was found on day 10 after TAM treatment, followed by a concomitant decrease of LCs in both epidermis and skin-draining LNs on days 15 and 30 post-TAM treatment (
During steady state, LCs locating to the epidermis are immature and barely express co-stimulatory molecules (e.g., CD80 and CD86). Upon exposure to inflammatory stimuli or during ex vivo culture, LCs undergo maturation by upregulating the expression of these co-stimulatory molecules and emigrate from the skin to the LNs, which is considered critical for T cell priming in response to inflammation. Thus, the spontaneous migration of HDAC3-deficient LCs may have resulted from the enhanced maturation of epidermal LCs in the absence of HDAC3.
HDAC3 mRNA expression in LCs from WT adult mice before and after ex vivo culture was over 70% lower in cultured mature LCs than in freshly isolated immature LCs (see example 5,
Langerhans cell histiocytosis (LCH) is a pediatric inflammatory myeloid neoplasm wherein myeloid lineage cells accumulate in tissues throughout the body. LCH was named for the presence of mutation-bearing myeloid cells that irregularly express langerin (CD207) and CD1a, molecules known to be expressed on Langerhans cells.
The most common mutation in LCH is BRAFV600E, which leads to constitutive activation of RAF-MEK-ERK signaling in the absence of mitogens. Constitutive activation of this signaling cascade causes the pathophysiologic changes observed in myeloid cells that drive LCH pathology. The BRAFV600E mutation causes mTOR-induced senescence-associated secretory phenotype, reduced apoptosis, abrogated tissue migration, and dysregulated hematopoiesis.
BMDC cultures were generated from mice bearing this mutation in myeloid lineage cells, which is a valuable tool for identifying drugs that can inhibit BRAFV600E-bearing DCs presumably LCH cells or LCH precursor cells
BMDCs are generated by isolating bone-marrow from mice and culturing the bone marrow in complete RPMI (cRPMI) supplemented with 20 ng/mL of granulocyte-macrophage colony-stimulating factor (GM-CSF) for 6 days. The small-molecule HDAC3 inhibitor, RGFP966 (
As expected, the cultures showed increased BMDC frequency from BRAFV600E mice compared to the BMDC frequency from WT mice (
In conclusion, the data in the disclosed examples demonstrates that HDAC3 plays a critical role as a key epigenetic regulator to control embryonic development, maintenance, and function of epidermal LCs. Importantly, the disclosure supports the use of HDAC3 inhibitors as a therapeutic treatment for the LC proliferative diseases LCH and LSC.
While the present disclosure has been described at some length and with some particularity with respect to the several described embodiments, it is not intended that it should be limited to any such particulars or embodiments or any particular embodiment, but it is to be construed with references to the appended claims so as to provide the broadest possible interpretation of such claims in view of the prior art and, therefore, to effectively encompass the intended scope of the disclosure.
All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, section headings, the materials, methods, and examples are illustrative only and not intended to be limiting.
This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63/246,962 filed Sep. 22, 2021, the contents of which are incorporated herein by referenced in its entirety.
This invention was made with government support under Grant No. AR069681 awarded by the National Institutes of Health (NIH). The Government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2022/076857 | 9/22/2022 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63246962 | Sep 2021 | US |
